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The critical role of the MAP kinase pathway in meiosis II in
Xenopus oocytes is mediated by p90Rsk
Stefan D. Gross*, Markus S. Schwab*, Frederic E. Taieb, Andrea L. Lewellyn,
Yue-Wei Qian and James L. Maller
Background: During oocyte maturation in Xenopus, progesterone induces entry
into meiosis I, and the M phases of meiosis I and II occur consecutively without
an intervening S phase. The mitogen-activated protein (MAP) kinase is activated
during meiotic entry, and it has been suggested that the linkage of M phases
reflects activation of the MAP kinase pathway and the failure to fully degrade
cyclin B during anaphase I. To analyze the function of the MAP kinase pathway in
oocyte maturation, we used U0126, a potent inhibitor of MAP kinase kinase, and
a constitutively active mutant of the protein kinase p90Rsk, a MAP kinase target.
Results: Even with complete inhibition of the MAP kinase pathway by U0126, up
to 90% of oocytes were able to enter meiosis I after progesterone treatment,
most likely through activation of the phosphatase Cdc25C by the polo-like
kinase Plx1. Subsequently, however, U0126-treated oocytes failed to form
metaphase I spindles, failed to reaccumulate cyclin B to a high level and failed to
hyperphosphorylate Cdc27, a component of the anaphase-promoting complex
(APC) that controls cyclin B degradation. Such oocytes entered S phase rather
than meiosis II. U0126-treated oocytes expressing a constitutively active form of
p90Rsk were able to reaccumulate cyclin B, hyperphosphorylate Cdc27 and form
metaphase spindles in the absence of detectable MAP kinase activity.
Conclusions: The MAP kinase pathway is not essential for entry into meiosis I
in Xenopus but is required during the onset of meiosis II to suppress entry into
S phase, to regulate the APC so as to support cyclin B accumulation, and to
support spindle formation. Moreover, one substrate of MAP kinase, p90Rsk, is
sufficient to mediate these effects during oocyte maturation.
Background
A hallmark of the eucaryotic cell cycle is the alternation of S
and M phases, even in the simple early embryonic cell
cycles that lack G1 and G2 phases. The major exception to
this rule occurs in meiosis, when two successive M phases
control the reduction divisions of meiosis I and II. The con-
trols that ensure successive meiotic M phases have been
studied most extensively in Xenopus oocytes undergoing
meiotic maturation. In particular, the activity of the mos
proto-oncogene product, a mitogen-activated protein (MAP)
kinase kinase kinase, is important for suppression of S phase
after meiosis I [1]. Mos is not sufficient, however, because
even ectopic overexpression of an active glutathione-S-
transferase (GST)–Mos fusion protein is unable to prevent
cyclin B degradation and exit from M phase after anaphase I
in the presence of cycloheximide [1,2]. Ordinarily, only 50%
of cyclin B is targeted for destruction by the anaphase-pro-
moting complex (APC) during exit from meiosis I, due in
part to increased cyclin B synthesis [2–4]. Changes in the
abundance of cyclin B have been correlated with changes in
the phosphorylation state and electrophoretic mobility of
the Cdc27 component of the APC [5].
MAP kinase activity has also been implicated at two other
control points in the oocyte maturation process [6–9]. In
oocytes arrested at the G2–prophase border, progesterone-
dependent entry into meiosis I is accompanied by the syn-
thesis of Mos [2,10,11]. Accumulation of Mos above a
threshold level [12] activates a MAP kinase pathway
[11,13,14] leading to the activation of maturation-promoting
factor (MPF), most likely through activation of a target of
MAP kinase, p90Rsk [15]. Activated p90Rsk inactivates
Myt1, a negative regulator of MPF [16], thereby promoting
activation of MPF and entry into meiosis I. The importance
of MAP kinase/Rsk activation is suggested by significant
inhibition of germinal vesicle breakdown (GVBD) by
experimental treatments that block activation of MAP
kinase [2,10,17,18]. Moreover, overexpression of Mos, MAP
kinase kinase or constitutively activated MAP kinase can
induce GVBD in meiosis I in a significant fraction of the
oocyte population in the absence of progesterone [19–22].
A third control point in oocyte maturation in which MAP
kinase has been implicated is in metaphase II arrest at the
end of meiosis II. The cytoplasmic activity responsible for
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metaphase arrest, originally termed cytostatic factor (CSF)
by Masui and Markert [23], is generated by the activated
MAP kinase pathway [6–9]. When assayed in blastomeres
of cleaving embryos, expression of either Mos, MAP kinase
kinase or thio-phosphorylated MAP kinase is sufficient to
cause CSF arrest [9,19,24,25]. More recently, a MAP kinase
target, the protein kinase p90Rsk, was shown to be the sole
mediator of CSF arrest: constitutively active Rsk caused
CSF arrest in the absence of an active MAP kinase pathway
[26], and depletion of Rsk from egg extracts removed CSF
activity, which could be restored by readdition of Rsk [27].
Studies of the role of Mos and the MAP kinase pathway at
various points in the oocyte maturation process have been
complicated by the inability to completely inhibit matura-
tion with reagents that inhibit Mos synthesis or block
MAP kinase kinase activity. This suggests that a non-
MAP kinase pathway might be sufficient to induce matu-
ration in the absence of an active MAP kinase pathway, at
least in a sub-population of oocytes. Possible alternative
pathways include those mediated by the protein kinase
Eg2 [28], and the polo-like kinase pathway involved in
activation of the phosphatase Cdc25C [29]. In this paper,
we report the results of studies with U0126, a new, more
potent inhibitor of MAP kinase kinase [30]. We found
that, in freshly isolated oocytes, the MAP kinase pathway
was not required for entry into meiosis I induced by prog-
esterone but was required for S-phase suppression, regula-
tion of cyclin B degradation by the APC, and spindle
formation during meiosis II. Moreover, these functions of
MAP kinase were mediated solely by p90Rsk.
Results
U0126 treatment does not block GVBD
Numerous studies have shown that activation of Mos,
MAP kinase kinase or MAP kinase is sufficient to induce
meiosis I in the absence of progesterone [6–9,19–22]. To
address whether MAP kinase activation is necessary
throughout the progesterone-dependent meiotic process,
U0126, an inhibitor of the MAP kinase kinase MEK1 was
used. Because U0126 can inhibit activated MEK1 [30], it
produces more complete inhibition than other drugs such
as PD98059, which function only to prevent MEK1 activa-
tion. Oocytes were induced to mature using progesterone,
in the presence or absence of U0126, and scored as a func-
tion of time for GVBD (onset of meiosis I) by the appear-
ance of a white spot. As shown in Figure 1a, 90% of the
inhibitor-treated oocytes underwent GVBD, albeit
delayed by more than an hour compared with controls.
Oocytes at GVBD, in the presence or absence of U0126,
were indistinguishable from one another either physically
or after cytological analysis (Figure 1b,c). A similar conclu-
sion was recently reported by Fisher et al. [31] using a less
specific inhibitor of MAP kinase activation, geldanamycin. 
Inhibitor treatment blocks MAP kinase and p90Rsk
activation but not synthesis of Mos
To confirm that U0126 was blocking the MAP kinase
pathway, MAP kinase assays using epidermal growth
factor (EGF) receptor peptide as substrate were con-
ducted on control and inhibitor-treated oocyte cytosols at
0 hours and 6 hours after progesterone addition (a time at
which both treatment groups had reached maximal
GVBD). Figure 2a shows that MAP kinase was dramati-
cally activated in control oocytes at GVBD, but unde-
tectable in resting oocytes or in U0126-treated oocytes at
GVBD. Immunoblots for activated MAP kinase (pMAPK),
and for p90Rsk showed that inhibitor treatment completely
eliminated phosphorylated (active) MAP kinase
immunoreactivity and the mobility shift of p90Rsk associ-
ated with MAP kinase phosphorylation during maturation
[32] (Figure 2b). These two observations show that MAP
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Figure 1
Effect of U0126 on oocyte maturation. (a) GVBD. Stage VI oocytes
were manually dissected from the ovary, cultured in 0.65 × DMEM with
50 µg/ml gentamycin and induced to mature using 100 ng/ml
progesterone. Either 50 µM U0126 or DMSO alone (control) was
added 1 h before addition of progesterone. Oocytes were scored as a
function of time for GVBD (observed as appearance of a distinctive
white spot). (b) Oocyte morphology. Control and inhibitor-treated
oocytes were collected immediately after GVBD, fixed in formaldehyde
and photographed. (c) Cytological analysis. Oocytes were fixed in
Perenyi’s fluid, embedded in Technovit 7100 (Energy Beam Sciences),
and sectioned at 4 µ. The arrows point to the yolk-free region below
the white spots in (b). GV, germinal vesicle; VI, resting stage VI oocyte;
CON, progesterone-treated oocyte with white spot; U0126,
progesterone + U0126-treated oocyte with white spot.
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kinase activity was completely inhibited by U0126. Inter-
estingly, although it was previously demonstrated that a
feedback loop that depends on the MAP kinase pathway
contributes to maximal Mos expression [2,19,33], initial
Mos accumulation appeared unaffected by inhibitor treat-
ment (Figure 2b), suggesting that a feedback loop from
MPF can lead to Mos accumulation independently of the
MAP kinase pathway [3,19]. To gain a better understand-
ing of MPF activation in the absence of the MAP kinase
pathway, the same oocyte extracts were immunoblotted
for Cdc25C and Plx1, the Xenopus homolog of the polo-
like kinase involved in activation of the phosphatase
Cdc25C [29] (Figure 2c). Previous work has shown that
activation of Plx1 at GVBD during maturation coincides
with an upward mobility shift due to phosphorylation [29].
As shown in Figure 2c, Plx1 underwent a full mobility
shift at GVBD in both control and inhibitor-treated
oocytes, demonstrating that Plx1 activation does not
require the MAP kinase pathway. 
Previous results have shown that expression of exogenous
Mos or constitutively active Plx1 is sufficient to cause
GVBD in the absence of progesterone [2,21,34,35].
Therefore, it was of interest to evaluate whether their
ability to cause GVBD relied on activation of the MAP
kinase pathway. In the case of Mos, bacterially-expressed
GST–Mos was microinjected into stage VI oocytes in the
presence and absence of U0126. As shown in Figure 3a,
although Mos efficiently induced maturation in control
oocytes, treatment with U0126 completely blocked Mos-
induced maturation. As expected, no detectable Mos-
dependent pMAP kinase signal was evident in the
presence of the inhibitor, and endogenous Mos synthesis
was not stimulated by GST–Mos (Figure 3a). These
results indicate that MEK1 is a required target of Mos for
activation of MPF in meiosis I, but do not exclude the
possibility that Mos might phosphorylate other substrates
as well when it induces maturation directly. If Mos has
another essential substrate other than MEK1, it might
explain why antisense oligonucleotides against Mos block
GVBD [2,9,10] but active Mos required the MAP kinase
pathway to elicit GVBD (Figure 3a). In contrast to these
results, injection of mRNA encoding a constitutively
active form of Plx1 induced GVBD and Cdc2 histone H1
kinase activation (Figure 3b) in the presence of U0126.
Thus, it is likely that activation of Plx1 may underlie the
mechanism for cyclin B–Cdc2 activation in U0126-treated
oocytes at meiosis I in the absence of the MAP kinase
pathway (Figure 1). Interestingly, a smaller fraction of
Cdc25 became fully activated (shifted) in the inhibitor-
treated oocytes compared with controls (Figure 2c), sug-
gesting at least some dependence on the MAP kinase
pathway for full activation of Cdc25C, although neither
Plx1 nor its activating kinase xPlkk1 are substrates for
MAP kinase [29,36]. This observation is consistent with
previous data showing that inhibition of Plx1 activation
does not completely suppress Cdc25C activation [29].
To assess the activation state of MPF (cyclin B–Cdc2) in
the control and inhibitor-treated oocytes, histone H1 kinase
assays were performed on extracts of oocytes collected at
the indicated times after progesterone addition (Figure 4a).
Histone H1 kinase activity increased during meiosis I in
both groups, and assays with p13SUC1 beads confirmed
that the increase was due to Cdc2 (Figure 4c). Histone H1
kinase activation in the U0126-treated oocytes was,
however, not as great as in the controls. Moreover, in the
inhibitor-treated oocytes, histone H1 kinase activity did not
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Figure 2
U0126 inhibits activation of both MAP kinase and p90Rsk but not of
Plx1. (a) MAP kinase activity. Homogenates prepared from control and
U0126-treated oocytes at 0 h and at GVBD were assayed for MAP
kinase activity using EGF receptor peptide as substrate, as described
in the Materials and methods. (b) Immunoblotting of MAP kinase
pathway components. Western blots of extracts of control and
inhibitor-treated oocytes during progesterone-induced maturation as in
Figure 1a are shown for Mos, pMAP kinase, and p90Rsk. (c) Analysis of
Plx1 and Cdc25C. Western blots of the oocyte extracts probed for
Plx1 and its substrate, Cdc25C.
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increase for up to 5 hours post-GVBD, when the control
oocytes were undergoing meiosis II with elevated histone
H1 kinase activity. Previous studies have shown that the
meiosis I→II transition is characterized by the degradation
of 50% of the cyclin B at anaphase I followed by re-accumu-
lation of cyclin B upon entry into meiosis II [2,37]. Western
blots indicated that the failure to reactivate cyclin B–Cdc2
in the presence of U0126 correlated strongly with the
failure to reaccumulate cyclin B (Figure 4b).
The reduced level of histone H1 kinase activity at GVBD
in the presence of U0126 (Figure 4a,c) was not associated
with a reduction in the level of cyclins B1 or B2 at GVBD
(Figure 4b) but was consistent with the reduced activation
of Cdc25C seen under these conditions (Figure 2c). If
Cdc25C was only partially activated, then it could be pre-
dicted that U0126-treated oocytes would have a higher
level of Tyr15-phosphorylated Cdc2–cyclin B (pre-MPF)
at GVBD than controls. Indeed, immunoblots of control
and U0126-treated oocytes revealed a higher level of tyro-
sine-phosphorylated Cdc2 at GVBD in the presence of
the drug (data not shown). The protein kinase that phos-
phorylates Cdc2 during maturation is Myt1, which is neg-
atively regulated by phosphorylation by both cyclin
B–Cdc2 and p90Rsk [15,16]. Cdc2-dependent phosphory-
lation and inactivation of Myt1 is associated with a large
decrease in electrophoretic mobility on SDS gels [16]. To
assess whether Myt1 regulation is altered in the presence
of U0126, mRNA encoding kinase-dead Myt1 was trans-
lated in a reticulocyte lysate and injected into oocytes.
Following progesterone treatment, with or without
U0126, samples of oocytes were analyzed for radiolabeled
Myt1 electrophoretic mobility by autoradiography and for
the level of phosphorylated Cdc2 by immunoblotting
(Figure 4d). Myt1 inactivation was delayed and the level
of phosphorylated Cdc2 persisted longer after proges-
terone addition during maturation in the presence of
U0126. These results could reflect altered activity of both
p90Rsk and cyclin B–Cdc2 but, in any case, they suggest
that the reduced Cdc2 histone H1 kinase activity at
GVBD in the presence of U0126 (Figure 4a) is due to
both reduced Cdc25C activation (Figure 2c) and delayed
Myt1 inactivation, resulting in a higher level of inactive
phosphorylated Cdc2–cyclin B.
Cyclin B degradation is dependent on the activity of a
ubiquitin ligase (E3) complex, the APC, in which Cdc27 is
a conserved component [38]. In Xenopus, cell-cycle-related
changes in APC activity towards cyclin B have been corre-
lated with changes in the electrophoretic mobility of
Cdc27 [5]. Western blots from both control and U0126-
treated oocytes demonstrate that Cdc27 undergoes a
mobility shift upwards, shortly after the onset of GVBD, a
time that coincides with anaphase I and cyclin B degrada-
tion (Figure 4b,c). This shift has previously been demon-
strated to correlate with activation of the APC [5]. At
4 hours after GVBD, however, when control oocytes enter
metaphase II, Cdc27 is further shifted in control but not in
U0126-treated oocytes (Figure 4b,c). This second mobility
shift has been reported to correlate with cyclin B2 stabi-
lization in Xenopus extracts [5], possibly reflecting inhibi-
tion of ubiquitination. The absence of hypershifted Cdc27
and a reduced level of cyclin B2 in U0126-treated oocytes
4–5 hours after GVBD (Figure 4b) suggests that, in the
absence of the MAP kinase pathway, cyclin B is rapidly
degraded because of higher activity of the APC. To assess
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Figure 3
Effect of U0126 on maturation induced by
GST–Mos or constitutively active Plx1.
(a) GST–Mos. Control and U0126-treated
oocytes were microinjected with 50 nl (50 ng)
GST–Mos and subsequently monitored at 8 h
for GVBD in comparison with control and
U0126-treated oocytes incubated with
progesterone (upper panel), or extracts were
prepared and immunoblotted for active MAP
kinase (pMAP kinase) or Mos (lower panel).
(b) Plx1 mRNA encoding DD Plx1 (Plx1
protein carrying the substitutions S128D and
T201D) [34] was injected into oocytes with or
without U0126 treatment. At the indicated
times, oocyte samples were analyzed for
histone H1 kinase activity (upper panel) or
immunoblotted for pMAP kinase (lower panel).
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this possibility directly, 35S-methionine-labeled cyclin B1
synthesized in a reticulocyte lysate was injected into
oocytes 4 hours after GVBD in the absence and presence
of U0126. Cyclin B1 was chosen because of previous evi-
dence that its degradation by the APC does not require
binding to Cdc2 [39]. As shown in Figure 5, in controls
with an active MAP kinase pathway, cyclin B1 had a half-
life of much greater than 30 minutes. In the presence of
U0126, however, the half-life decreased dramatically to
less than 15 minutes. These changes in stability were asso-
ciated with the expected changes in mobility of Cdc27.
Cyclin B1 lacking the destruction box that targets it for
APC-mediated degradation was not degraded in the pres-
ence or absence of U0126 (Figure 5a). These results indi-
cate the MAP kinase pathway increases the level of cyclin
B in meiosis II by inhibiting APC-mediated degradation.
U0126 treatment induces DNA replication after meiosis I
We analyzed whether U0126-treated oocytes (Figure 4)
remained in M phase after meiosis I or were instead forming
nuclei, entering S phase, and undergoing DNA replication
in a manner similar to that previously reported for maturing
oocytes after cycloheximide treatment or after inhibition of
Mos during the meiosis I→II transition [1,2]. Cytological
analysis indicated that meiosis I spindles cannot be detected
after GVBD (data not shown). Instead, as shown in
Figure 6, both the U0126- and cycloheximide-treated
oocytes underwent DNA replication after GVBD, a process
that requires assembly of a nuclear envelope [40]. Aphidi-
colin treatment of the U0126-treated oocytes completely
abolished dCTP incorporation, indicating that DNA replica-
tion rather than DNA repair was occurring. Entry into
meiosis II and suppression of DNA replication have been
434 Current Biology Vol 10 No 8
Figure 4
Biochemical analysis of U0126-treated oocytes. (a) Histone H1 kinase
activity. Control or U0126-treated oocytes were isolated at the
indicated times, homogenized in EB (see the Materials and methods)
and assayed for histone H1 kinase activity. The time points post-GVBD
are normalized for the delay in GVBD caused by U0126 (Figure 1a).
Pg, progesterone. (b) Analysis of the same lysates by immunoblotting
for cyclin B1, cyclin B2 and Cdc27. (c) At the indicated times, lysates
from control and U0126-treated oocytes were immunoblotted for cyclin
B1, cyclin B2 and Cdc27 or assayed for Suc1-associated histone H1
kinase activity. (d) Effect of U0126 on Myt1 during maturation. The
mRNA encoding kinase-dead Myt1 was translated in a reticulocyte
lysate containing [35S]methionine as described in the Materials and
methods and injected into oocytes just before progesterone treatment
in the absence (control) or presence of U0126. At the indicated times,
oocytes were homogenized, samples electrophoresed on 10% gels
and processed for autoradiography (upper panel) or transferred to
nitrocellulose and probed with antibodies against tyrosine-
phosphorylated Cdc2 (pCdc2; lower panel). MII, metaphase II.
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shown to be dependent on the synthesis of both Mos and
cyclin B [1,2]. Our experiments suggest that the require-
ment for Mos to suppress DNA synthesis is mediated exclu-
sively by MAP kinase activation. The fact that in
U0126-treated oocytes the APC remains active for cyclin B
degradation (Figure 5) may in part account for M-phase exit.
The protein kinase p90Rsk is a proximal target of MAP
kinase that becomes fully activated during oocyte matura-
tion [32]. We previously reported the generation of a con-
stitutively active form of p90Rsk that also exhibits elevated
specific activity at GVBD compared with wild-type p90Rsk
[26]. Because p90Rsk is the downstream substrate for MAP
kinase sufficient to account for MAP kinase-dependent
metaphase arrest (CSF arrest) at the end of meiosis II
[26,27], we assessed the effect of expression of activated
p90Rsk on entry into meiosis II in the presence of U0126.
As shown in Figure 7, expression of constitutively active
Rsk but not β-galactosidase restored the Cdc27 hypershift
and the elevated level of cyclin B2 indicative of meiosis II.
Moreover, U0126-treated oocytes expressing constitu-
tively active Rsk were found to contain metaphase spin-
dles characteristic of meiosis II (Figure 7b), whereas none
were found in those treated with U0126 (data not shown),
which were synthesizing DNA (Figure 6). The results
indicate that the sole target of MAP kinase required for
regulation of events in meiosis II is p90Rsk. 
Discussion
Numerous studies have demonstrated that activation of
the MAP kinase pathway is sufficient to induce maturation
in oocytes. Until now, however, it has not been clear
whether MAP kinase is necessary for this process. Early
work showed that injection of antisense oligonucleotides
against Mos blocks MPF activation and GVBD in 60–70%
of oocytes [10]. More recently, injection of MEK antibod-
ies into Xenopus oocytes has been reported to significantly
block MAP kinase activation and the subsequent activa-
tion of MPF and induction of maturation [17]. In addi-
tion, overexpression of MKP-1, the MAP kinase
superfamily-specific phosphatase, has been shown to
block MAP kinase and MPF activation, and Mos accumu-
lation and maturation [19]. Nevertheless, as initially
reported by others, in all of these studies the fraction of
the oocyte population sensitive to inhibitors of the MAP
kinase pathway varies [9]. In our hands, oocytes incu-
bated overnight before use mature more slowly in
response to progesterone, require a higher concentration
of progesterone and are more sensitive to inhibition of the
MAP kinase pathway. The results presented here were
conducted with freshly isolated oocytes in which inhibi-
tion of the MAP kinase pathway only altered the kinetics
rather than the extent of maturation (Figure 1). Similarly,
overexpression of a kinase-inactive mutant of Raf-1
causes only slightly slower kinetics and a reduced per-
centage of progesterone-induced GVBD due to the
absence of MAP kinase activity [41]. Together, these
results suggest that an alternative, MAP-kinase-indepen-
dent pathway may exist to initiate MPF activation in
response to progesterone. A similar conclusion was
recently reported by Fisher et al. [31] using a different
inhibitor to block MAP kinase activation. Our results
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Figure 5
Cyclin B1 degradation in control and U0126-
treated oocytes. Control and U0126-treated
oocytes were induced to enter GVBD by
treatment with progesterone. Oocytes were
collected 4 h after GVBD, pre-incubated
15 min in medium plus 10 mM chlorobutanol
and injected with 50 nl [35S]methionine-labeled
cyclin B1 or ∆N cyclin B1 translated in a
reticulocyte lysate as described in the Materials
and methods. (a) Oocytes were homogenized
at the indicated times and samples were
electrophoresed on 10% gels and either
processed for autoradiography (upper two
panels) or transferred to nitrocellulose and
probed with anti-Cdc27 antibodies (lower
panel). (b) The autoradiographs in (a) were
scanned with an Alpha Innotech imaging
system and the relative levels of cyclin B1
plotted as a function of time after injection.
(c) Relative levels of [35S]methionine-labeled
cyclin B1 from three independent experiments
were quantified by densitometry of
autoradiographs like the one shown in (a). The
reduced cyclin degradation in the presence of
U0126 was statistically significant (p < 0.05).
bb10h31.qxd  04/17/2000  12:57  Page 435
436 Current Biology Vol 10 No 8
indicate that the progesterone-dependent, MAP kinase-
independent pathway leading to MPF activation and
meiosis I (Figures 1, 2 and 8) is the Plx1 kinase cascade.
MAP kinase does, however, appear to be required for
meiosis II, in that, after GVBD, U0126-treated oocytes
exited meiosis and soon thereafter initiated DNA replica-
tion instead of meiosis II. In addition, in these oocytes,
Cdc27 did not become hyperphosphorylated and direct
injection of radiolabeled cyclin B indicated that the APC
was more active in the absence of MAP kinase (Figure 5).
Our results support the earlier evidence [5] that changes in
the mobility of Cdc27 are accurate reflections of APC
activity in oocytes. Cycloheximide treatment of GVBD
oocytes also blocks meiosis II and induces DNA replica-
tion, an effect that may be linked to reduction of Mos and
cyclin B levels, as previously reported [1,2]. U0126 treat-
ment does not prevent Mos accumulation but does prevent
increased MAP kinase activity, accumulation of cyclin B
after meiosis I, and the corresponding increase in histone
H1 kinase activity essential for meiosis II and arrest at
second meiotic metaphase (Figures 2 and 4). This suggests
that MAP kinase is required after GVBD for accumulation
of cyclin B to a level that ensures S phase is not induced
after anaphase I. This reflects effects of the MAP kinase
pathway in meiosis II on cyclin B degradation by the APC
(Figure 5). At present, the data cannot distinguish between
a direct effect of the MAP kinase pathway/p90Rsk on the
APC itself versus an effect on a possible inhibitor of the
APC [5]. Although a detectable level of cyclin B was
present in S-phase oocytes after U0126 treatment, histone
H1 kinase activity was low (Figure 4) and Cdc2 was pre-
dominantly in the inactive tyrosine-phosphorylated state.
This suggests that the ‘threshold level’ of cyclin B–Cdc2
activity needed to define a G2/M cell [42] requires the
reaccumulation of cyclin B to the higher level afforded by
an active MAP kinase pathway.
An activated form of the MAP kinase substrate p90Rsk was
able to promote reaccumulation of cyclin B, Cdc27 hyper-
phosphorylation and spindle formation, suggesting that it
is directly capable of controlling these events. As constitu-
tively active Rsk produced these effects in the presence of
U0126, Rsk is the sole substrate of MAP kinase required
for these effects. Whether Rsk acts directly or indirectly
on the APC or also on cyclin B synthesis remains to be
determined. Nevertheless, combined with the previous
evidence that p90Rsk activation is necessary and sufficient
to explain MAP-kinase-dependent arrest at metaphase II
(CSF arrest) [26,27], these results indicate that Rsk is suf-
ficient at multiple points in meiosis II to execute the func-
tions of the MAP kinase pathway. 
Materials and methods
Oocyte injection and treatments
X. laevis females were obtained from Xenopus I and primed with 35 I.U.
pregnant mare’s serum gonadotropin 3–5 days before manual dissection
Figure 6
U0126 treatment induces DNA replication in post-meiosis I oocytes.
Control oocytes and oocytes pretreated with 50 µM U0126 for 1 h
(lanes 6–9) were injected with 50 nl [α-32P]dCTP (3000 Ci/mmol;
10 µCi/µl) and maturation induced using 100 ng/ml progesterone.
Control oocytes were collected 3 h after injection (before GVBD had
occurred, lane 1), and 2 h and 4 h after GVBD (lanes 2,3). Some
oocytes were transferred into medium containing 100 µg/ml
cycloheximide (CHX) 30–60 min after GVBD (lanes 4,5). Aphidicolin
(APD, 20 µg/ml) was added to some U0126-treated oocytes within
15 min after GVBD (lanes 8,9). Oocytes were collected at the
indicated times after the corresponding treatments (lanes 4–9),
followed by lysis, proteinase K treatment and extraction of the DNA [1].
DNA corresponding to three oocytes was loaded on a 0.9% agarose
gel, electrophoresed and processed for autoradiography.
Figure 7
Rsk mediates effects of the MAP kinase pathway on the meiosis I to II
transition. (a) Uninjected oocytes, or oocytes expressing either a
constitutively active form [26] of p90Rsk (CA-Rsk) or β-galactosidase
(β-gal), were treated with progesterone in the presence or absence of
U0126. At GVBD and 4 h later, at metaphase II (MII), oocytes were
collected and immunoblotted for the level of cyclin B2 and the mobility
of Cdc27. (b) Control oocytes or U0126-treated oocytes injected with
mRNA encoding CA-Rsk were analyzed for metaphase spindles. No
spindles were formed in oocytes treated with U0126 alone that were
synthesizing DNA (Figure 6). Similar results were obtained in 10
independent analyses.
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of oocytes from excised ovary fragments. Injection of oocytes and induc-
tion of maturation by progesterone (100 ng/ml) were as described previ-
ously [26]. Extraction of oocytes and assays for histone H1 kinase activity
or MAP kinase activity are described elsewhere [2,43]. Immunoblotting
procedures and the antibodies used to follow cyclin B, Mos, Rsk, acti-
vated MAP kinase and Cdc27 have also been described elsewhere
[2,26,32,44]. U0126 was obtained from Promega and dissolved in
DMSO before addition to a final concentration of 50 µM. The control
oocyte population was treated with DMSO alone. U0126 was generally
present for 1 h before progesterone addition. The mRNA encoding con-
stitutively active Rsk or β-galactosidase was prepared with a mMessage
mMachine kit (Ambion) as described [26] and injected in 30 nl volumes
into oocytes at a concentration of 1.0 mg/ml. The cDNA encoding cyclin
B1 lacking the destruction box by deletion of sequence encoding amino
acids 1–44 (∆N-cyclin B1) was generated by PCR using the primers 5′-
GACGACGACAAGATGGCAGAGGTGAAAGTG-3′ and 5′-GAGGA-
GAAGCCCGTTCACATGAGTGGGCGGGC-3′ and Xenopus cyclin B1
in pET3 as template. The amplified fragment was cloned into cCITE-LIC
vector according to the manufacturer’s protocol (Novagen). The Myt1
cDNA (kind gift of A. Nebreda, [15]) was cloned into the pET30-4C
vector and Asn231 was then changed to Ala using the Quickchange pro-
cedure (Stratagene) to create a kinase-dead mutant. Cyclin B in pET3
vector, ∆N-cyclin B1 in pCITE vector, and Myt1 N/A in pET30 vector
were translated in a reticulocyte lysate (TnT7 Quick Transcription Transla-
tion System, Promega) in the presence of [35S]methionine (ICN). Unincor-
porated [35S]methionine was removed with a Vivaspin filter unit (ISC
BioExpress) and the radiolabeled proteins equilibrated with injection
buffer (20 mM Hepes, pH 7.5, 88 mM NaCl, 7.5 mM MgCl2, 10 mM β-
mercaptoethanol). For experiments studying the degradation of 35S-cyclin
B, oocytes were induced to enter GVBD by treatment with progesterone
(100 ng/ml). To prevent parthenogenetic activation by the microinjection
pipet, 4 h after GVBD, oocytes were incubated in medium containing
10 mM chlorobutanol for 10 min before injection, during the injection, and
after injection of 50 nl 35S-labeled cyclin B1 or ∆N-cyclin B1. Oocytes
were collected and homogenized in EB (80 mM β-glycerophosphate,
20n mM EGTA, 15 mM MgCl2, 1 mM DTT, 1 × protease inhibitor cocktail
(Complete, Roche)) at the indicated times after injection and analyzed by
SDS–PAGE and autoradiography. 35S-Myt1 was injected into resting
oocytes that were then treated with progesterone (100 ng/ml) to induce
GVBD. Oocytes were collected and homogenized in EB at the indicated
times and analyzed by SDS–PAGE and autoradiography. Bacterially
expressed GST–Mos was prepared as described previously [2]. For DNA
synthesis measurements, [α-32P]dCTP (3000 Ci/mmol, 10 mCi/ml) was
injected just before progesterone treatment. For analysis, oocytes were
lysed, treated with proteinase K, extracted with phenol/chloroform, and
analyzed by agarose gel chromatography and autoradiography as
described [1]. Where used, aphidicolin (20 µg/ml) was added to the
medium within 15 min of GVBD, before detectable DNA synthesis
occurred in controls. Confocal analysis of oocytes and staining for
metaphase spindles was carried out as previously described [26].
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